Jazz Expensed $754.2 Million Of Its Actio Deal At Once, Turning Record Revenue Into A Loss

Jazz booked a $413.4 million operating loss on $1.24 billion of revenue as it also spent $225.0 million on buybacks.

Share
Jazz Expensed $754.2 Million Of Its Actio Deal At Once, Turning Record Revenue Into A Loss

Jazz Pharmaceuticals, which develops medicines for rare diseases in sleep disorders, epilepsy and cancer, charged $754.2 million to expense in the third quarter for the research asset it got in buying Actio Biosciences. That pushed the company to a $413.4 million operating loss, against a $57.5 million operating profit a year earlier, even as revenue reached $1.243 billion, its 10-Q filed Monday shows.

Almost the whole price, expensed

Total consideration for Actio came to $850.7 million: an $820.0 million upfront payment, $19.9 million of cash acquired and $10.8 million of transaction costs, less the cash that came with the company. Of that, $754.2 million went to in-process research on ABS-1230, which Jazz expensed because it found no alternative future use for it. Only $57.6 million was booked as a deferred tax asset.

Net loss for the quarter was $483.4 million, or $7.48 a share, versus net income of $251.4 million a year earlier. Revenue rose 10% from $1.126 billion. The company's earnings release put the write-off's per-share hit at $11.32.

ABS-1230 is an experimental drug that blocks the KCNT1 ion channel, tested in a trial designed to support a future approval application. Jazz also agreed to pay up to $500.0 million more if regulatory and commercial milestones are met. Jazz said it expects to present initial patient data at a medical meeting in the fourth quarter.

Buybacks and a new $500 million program

Jazz spent $225.0 million buying back 0.9 million shares at $249.29 each, in privately negotiated deals with one of the initial purchasers of its new 2032 exchangeable notes. That used up the program the board authorized in July 2024. In October the board approved a new program of up to $500.0 million.

The 2032 notes, $1.3 billion in principal, carry a 1.875% coupon and an initial exchange price of about $355.24 a share. The 2030 notes moved to current liabilities because the stock traded above 130% of their $153.05 conversion price. None had been exchanged as of the filing date. Jazz held $2.9 billion in cash and investments and had $5.6 billion of long-term debt principal at September 30.

Lawsuit and competition risks

Jazz inherited Praxis's trade secret suit against Actio and former CEO David Goldstein. Praxis alleges Goldstein breached an advisory agreement and that they misappropriated its secrets on KCNT1 compounds. Trial is scheduled to begin July 31, 2028. The risk factors warn an adverse ruling could limit or preclude development of ABS-1230.

In sleep, Xywav sales rose 12% to $482.8 million, and about 17,550 patients were taking it at quarter end. The filing flags stiffer narcolepsy type 1 competition from Takeda's Orzeyful, an oral orexin 2 receptor agonist and the first of its kind FDA has approved. Epidiolex sales fell 2% to $295.4 million, and Zepzelca lost its second-line indication on September 30.

The FDA's target decision date for Jazz's cannabidiol capsule application is April 16, 2027.

Sources

More on Jazz Pharmaceuticals

All Jazz Pharmaceuticals (JAZZ) coverage →